Table 1. Transition probabilities.
| Phase and population | Parameters | VPZ 20 mg QD | PPI standard dose QD | VPZ 10 mg QD | PPI low dose QD | Treatment cessation |
|---|---|---|---|---|---|---|
| Healing rate during healing therapy | ||||||
| All RE patients | Healing rate at week 4 | 90% | 74% | |||
| Healing rate at week 8 | 94% | 87% | ||||
| Healing rate at weeks 4–8* | 40% | 50% | ||||
| LA C/D RE patients | Healing rate at week 4 | 90% | 61% | |||
| Healing rate at week 8 | 96% | 79% | ||||
| Healing rate at weeks 4–8* | 60% | 46% | ||||
| Relapse rate during maintenance therapy | ||||||
| All RE patients | Relapse rate in 6 months | 5% | 18% | |||
| Relapse rate in 4 weeks | 0.87% | 3.25% | ||||
| LA C/D RE patients | Relapse rate in 6 months | 13% | 29% | |||
| Relapse rate in 4 weeks | 2.33% | 5.55% | ||||
| Relapse rate after treatment cessation | ||||||
| All RE patients and LA C/D RE patients | Relapse rate in 6 months | 80% [9] | ||||
| Relapse rate in 4 weeks | 23.5% | |||||
*, healing rate at weeks 4–8 calculated by (healing rate at week 8 – healing rate at week 4)/(1 – healing rate at week 4). LA C/D, as Los Angeles grade C/D; PPI, proton pump inhibitors; QD, once daily; RE, reflux esophagitis; VPZ, vonoprazan.